Crinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees.

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH


Crinetics announces positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant, a candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome.

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference


Crinetics to present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time.

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer


Crinetics announces the appointment of Isabel Kalofonos as Chief Commercial Officer to lead global commercial strategy for the company’s first drug launch and its innovative pipeline of candidates.

Crinetics Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new non-executive employees.